Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TailorDose-II: Therapeutic dose monitoring of cytostatic drugs in breast cancer
2017-000641-44Phase 4Active
- Sponsor
- Karolinska Institutet
- Start
- Feb 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epirubicin, cyclophosphamide, docetaxel, paclitaxel and doxorubicin in breast cancer, sponsored by Karolinska Institutet. Primary endpoint: Incidence of grade 1-2 anemia in high vs. low exposure groups. Started Feb 2017; status: active.
02
Drugs
epirubicincyclophosphamidedocetaxelpaclitaxeldoxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-000641-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000641-44.